TABULA RASA HEALTHCARE,INC (NASDAQ:TRHC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

TABULA RASA HEALTHCARE,INC (NASDAQ:TRHC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

(d) On March5, 2019, the Board of Directors (the “Board”) of Tabula Rasa HealthCare,Inc. (the “Company”) increased the size of the Board from eight directors to nine directors and appointed Rear Admiral (“RADM”) Pamela Schweitzer, Pharm.D., as a director of the Board. RADM Schweitzer will serve as a ClassII director, to serve until the 2021 annual meeting of stockholders or until her earlier resignation, retirement or other termination of service. In connection with the adoption of a revised Board committee structure (as described below), the Board named RADM Schweitzer to serve as a member of each of the Nominating Committee and the Corporate Governance Committee. The Board has determined that RADM Schweitzer is an independent director in accordance with applicable rulesof the Securities and Exchange Commission (the “SEC”) and the Nasdaq Stock Market. RADM Schweitzer will be compensated in accordance with the non-employee director compensation program of the Board, as described in the Company’s Proxy Statement filed with the SEC on May1, 2018.

RADM Schweitzer, 59, has undertaken various speaking engagements since September2018. Previously, she served as the Assistant Surgeon General and Chief Pharmacist Officer of the U.S. Public Health Service (“PHS”) from August2014 through September2018. RADM Schweitzer served as a technical director in two divisions of the U.S. Centers for Medicare and Medicaid Services (“CMS”) from February2013 to August2018. Over the course of her career, RADM Schweitzer has served in varied assignments in the U.S. Indian Health Service (“IHS”), U.S. Veterans Administration and with the CMS. RADM Schweitzer earned her Doctor of Pharmacy from the University of California San Francisco School of Pharmacy and holds a Bachelor’s degree in Biological Sciences from California State University Fullerton. She completed an Ambulatory Care/Administrative Residency at University of California Irvine Medical Center and is a Board Certified Ambulatory Care Pharmacist. She is currently completing the Executive Master of Health Administration Program at the University of Southern California Sol Price School of Public Policy. The Board believes that RADM Schweitzer’s extensive leadership experience in public service and expertise in pharmacy programs will make her a valuable member of the Company’s Board.

In connection with her appointment, RADM Schweitzer will enter into the Company’s standard indemnification agreement, the form of which was previously filed with the Company’s Registration Statement on FormS-1 (Registration No.333-208857) in connection with the Company’s initial public offering completed in October2016. There is no other material Company plan, contract or arrangement in which RADM Schweitzer will participate in connection with her appointments. There are no arrangements or understandings between RADM Schweitzer and any other person to which RADM Schweitzer was selected as a director of the Company, and there is no family relationship between RADM Schweitzer and any of the Company’s other directors or executive officers. There are also no related party transactions between either of RADM Schweitzer and the Company.

Item 7.01Regulation FD Disclosure.

On March6, 2019, the Company issued a press release announcing RADM Schweitzer’s appointment to the Board. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit99.1.

The information provided in this Item 7.01 of this Current Report on Form8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed to be incorporated by reference in any filing made by the Company to the Securities Act or the Exchange Act other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.

Item 8.01 Other Events

At its meeting held on March5, 2019, the Board approved a revised Board committee structure that terminates the existing Nominating and Corporate Governance Committee and designates a separate Nominating Committee and Corporate Governance Committee. The revised Board committee structure and related committee membership changes became effective immediately. As of March5, 2019, the Board will have the following standing committees: Audit Committee, Compensation Committee, Nominating Committee and Corporate Governance Committee.

In addition to approving the revised Board committee structure, the Board approved a Nominating Committee charter and a Corporate Governance Committee charter to replace the former Nominating and Corporate Governance Committee charter and set forth the responsibilities of each respective committee. The Company will post copies of the new Nominating Committee charter and Corporate Governance Committee charter in the “Corporate Governance” section of the “Investors” pageof its corporate website at

In connection with the implementation of the revised Board Committee structure, the Board also made several appointments and changes in committee membership. The membership of each Board committee is as follows:

Nominating Committee

Corporate Governance Committee

Dennis Helling (chairperson)

A Gordon Tunstall (chairperson)

Jan Berger

Samira Beckwith

RADM Pamela Schweitzer

Jan Berger

Dennis Helling

Audit Committee

Kathrine O’Brien

Michael Purcell (chairperson)

Michael Purcell

A Gordon Tunstall

RADM Pamela Schweitzer

Samira Beckwith

Compensation Committee

Samira Beckwith (chairperson)

Kathrine O’Brien

Jan Berger

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Tabula Rasa HealthCare, Inc. Exhibit
EX-99.1 2 a19-5881_1ex99d1.htm EX-99.1 Exhibit 99.1     Tabula Rasa HealthCare Appoints New Member to its Board of Directors Rear Admiral Pamela Schweitzer,…
To view the full exhibit click here


Tabula Rasa HealthCare, Inc. (Tabula Rasa), formerly CareKinesis, Inc., is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs. It also provides risk adjustment services, which help its clients to properly characterize a patient’s acuity, or severity of health condition, and optimize the associated payments for care. The Company serves approximately 100 healthcare organizations that focus on populations with complex healthcare needs and extensive medication requirements. Its products and services are built around the Medication Risk Mitigation Matrix, or MRM Matrix.

An ad to help with our costs